INTRODUCTION {#s1}
============

Although the most important etiological agent in cervical cancer is human papillomavirus (HPV) infection, only a small proportion of infected women developed cervical cancer. HPV infection alone is insufficient to induce malignant changes. Copy number variation (CNV) is a very common phenomenon in cervical cancer and may be important in its pathogenesis \[[@R1]\]. Comparative genomic hybridization (CGH) studies for cervical cancer progression have shown that chromosome 3q gain was associated with the transition from pre-invasive to invasive cervical carcinoma. Subsequently, array-based CGH (aCGH), where arrays of genomic sequences replaced metaphase chromosomes as hybridization targets, was established. More detailed and precise genomic variations had been found in cervical cancer by using aGCH \[[@R2]\]. Lando et al. reported several potential driver genes for cervical carcinogenesis aCGH \[[@R3]\]. However, a recent study reported a limited correlation between chromosomal CNV and gene expression by single nucleotide polymorphisms array platform \[[@R4]\].

In this study, a high resolution Human Genome CGH Microarray Kit was used to detect genome-wide chromosomal CNV in 6 cervical cancer cell lines. We also performed gene expression studies in the cervical cancer cell lines, cervical carcinoma tissues and normal cervical epithelia by using Whole Human Genome Microarray Kit. Using appropriate bioinformatics software, we identified several chromosomal CNV regions and aberrantly expressed genes in cervical cancer. Statistical analysis and gene annotation analysis were also performed for the array data.

RESULTS {#s2}
=======

Fifty common chromosomal CNVs were identified in cervical cancer cell lines {#s2_1}
---------------------------------------------------------------------------

Using aCGH at a genome-wide resolution of 250 kb, a total of 50 common chromosomal CNV regions were identified, ranging from 0.5 Mb to 80 Mb. Of these, 21 common amplification regions (including 13 significant amplification regions) and 29 deletion regions (including 2 significant deletion regions) were identified (Table [1](#T1){ref-type="table"}).

###### Physical location of the chromosome CNV regions identified by array CGH in cervical cancer cell lines

  Region                         Region length   Cytoband location   Event   Genes   Frequency %   P-value   Reference
  ------------------------------ --------------- ------------------- ------- ------- ------------- --------- ---------------------------------------------------------------------------------------------------------------------------------------
  chr1:10001-3752828             3,742,828       p36.33 - p36.32     Gain    70      83.33333333   0.003     Gopeshwar Narayan, et al., 2007; Connie P. Matthews, et al., 2000; Y.W. CHOI, et al., 2007
  chr2:75161025-85137285         9,976,261       p12 - p11.2         Loss    17      83.33333333   0.006     Y.W. CHOI^\*^, et al., 2007
  chr2:137,395,646-170,227,851   32,832,206      q21.3 - q31.1       Loss    84      100           \>0.05    F.Y. Huang et al.2005; Y.W. CHOI, et al., 2007
  chr2:178,374,598-197,908,813   19,534,216      q31.2 - q33.1       Loss    67      83.33333333   \>0.05    F.Y. Huang et al.2005; Y.W. CHOI, et al., 2007
  chr2:209,391,516-216,053,786   6,662,271       q34 - q35           Loss    15      83.33333333   \>0.05    Lockwood WW, et al., 2007; F.Y. Huang et al.2005; G Ng, et al., 2007
  chr3:60,001-8,582,632          8,522,632       p26.3 - p25.3       Loss    15      83.33333333   \>0.05    F.Y. Huang et al.2005; Connie P. Matthews, et al., 2000; Y.W. CHOI, et al., 2007
  chr3:16,297,340-37,460,259     21,162,920      p25.1 - p22.2       Loss    60      83.33333333   \>0.05    Lockwood WW, et al., 2007; F.Y. Huang et al.2005; Connie P. Matthews, et al., 2000
  chr3:58,690,297-90,181,487     31,491,191      p14.2 - p11.1       Loss    52      83.33333333   0.028     Lockwood WW, et al., 2007; F.Y. Huang et al.2005; Connie P. Matthews, et al., 2000; Y.W. CHOI, et al., 2007; G Ng, et al., 2007
  chr3:93,605,515-101,219,924    7,614,410       q11.2 - q12.3       Loss    38      83.33333333   \>0.05    N/A
  chr4:10,479,679-39,591,168     29,111,490      p16.1 - p14         Loss    62      83.33333333   \>0.05    Lockwood WW, et al., 2007; F.Y. Huang et al.2005; Y.W. CHOI, et al., 2007; G Ng, et al., 2007
  chr4:41,596,003-44,365,208     2,769,206       p13                 Loss    10      83.33333333   \>0.05    Lockwood WW, et al., 2007; F.Y. Huang et al.2005; G Ng, et al., 2007
  chr4:58,367,789-139,871,504    81,503,716      q12 - q31.1         Loss    300     83.33333333   \>0.05    Lockwood WW, et al., 2007; G Ng, et al., 2007
  chr4:141,329,535-182,773,601   41,444,067      q31.1 - q34.3       Loss    127     83.33333333   \>0.05    Lockwood WW, et al., 2007; Y.W. CHOI, et al., 2007; G Ng, et al., 2007
  chr5:49,690,172-58,526,175     8,836,004       q11.1 - q11.2       Loss    35      83.33333333   \>0.05    Connie P. Matthews, et al., 2000
  chr6:44,372,753-58,614,061     14,241,309      p21.1 - p11.2       Loss    69      83.33333333   \>0.05    Connie P. Matthews, et al., 2000; Y.W. CHOI, et al., 2007
  chr6:61,982,931-73,725,450     11,742,520      q11.1 - q13         Loss    16      83.33333333   \>0.05    Connie P. Matthews, et al., 2000
  chr6:75,067,155-105,246,238    30,179,084      q13 - q21           Loss    83      83.33333333   \>0.05    Connie P. Matthews, et al., 2000
  chr6:112,398,800-148,256,165   35,857,366      q21 - q24.3         Loss    143     83.33333333   \>0.05    Connie P. Matthews, et al., 2000; Y.W. CHOI, et al., 2007
  chr7:76,075,269-97,170,202     21,094,934      q11.23 - q21.3      Loss    77      83.33333333   \>0.05    N/A
  chr7:105,159,121-110,522,522   5,363,402       q22.3 - q31.1       Loss    24      83.33333333   \>0.05    N/A
  chr8:12,830,587-20,081,624     7,251,038       p22 - p21.3         Loss    27      83.33333333   \>0.05    Lockwood WW, et al., 2007; G Ng, et al., 2007
  chr8:75,336,800-85,510,468     10,173,669      q21.11 - q21.2      Loss    27      83.33333333   \>0.05    N/A
  chr8:142,141,881-146,304,022   4,162,142       q24.3               Gain    92      83.33333333   0         Gopeshwar Narayan, et al., 2007; F.Y. Huang et al.2005; Connie P. Matthews, et al., 2000; Y.W. CHOI, et al., 2007; G Ng, et al., 2007
  chr9:128,223,213-139,309,447   11,086,235      q33.3 - q34.3       Gain    211     83.33333333   0.017     Lockwood WW, et al., 2007; Y.W. CHOI, et al., 2007
  chr11:60,001-3,696,670         3,636,670       p15.5 - p15.4       Gain    85      83.33333333   0         Y.W. CHOI, et al., 2007; G Ng, et al., 2007
  chr11:20,658,997-31,795,373    11,136,377      p15.1 - p13         Loss    27      83.33333333   \>0.05    F.Y. Huang et al.2005
  chr11:65,627,563-67,839,841    2,212,279       q13.1 - q13.2       Gain    77      83.33333333   0.003     Y.W. CHOI, et al., 2007
  chr12:38,766,104-42,827,028    4,060,925       q12                 Loss    12      83.33333333   \>0.05    N/A
  chr13:45,697,630-55,761,181    10,063,552      q14.12 - q21.1      Loss    56      83.33333333   \>0.05    Lockwood WW, et al., 2007; G Ng, et al., 2007
  chr14:23,251,874-24,898,017    1,646,144       q11.2- q12          Gain    64      83.33333333   0.001     N/A
  chr16:60,001-3,153,334         3,093,334       p13.3               Gain    137     83.33333333   0.048     Y.W. CHOI, et al., 2007
  chr16:3,970,244-5,071,063      1,100,820       p13.3               Gain    23      83.33333333   0.048     Y.W. CHOI, et al., 2007
  chr16:28,276,920-31,195,342    2,918,423       p11.2               Gain    100     83.33333333   0.048     Y.W. CHOI, et al., 2007
  chr16:66,279,668-70,782,910    4,503,243       q21 - q22.1         Gain    103     83.33333333   0.021     Lockwood WW, et al., 2007; Connie P. Matthews, et al., 2000
  chr16:83,959,097-90,294,753    6,335,657       q23.3 - q24.3       Gain    78      83.33333333   0.021     Lockwood WW, et al., 2007; Connie P. Matthews, et al., 2000; Y.W. CHOI, et al., 2007
  chr17:7,175,150-8,229,647      1,054,498       p13.1               Gain    59      83.33333333   0.009     N/A
  chr17:72,693,870-81,060,000    8,366,131       q25.1 - q25.3       Gain    166     83.33333333   \>0.05    Lockwood WW, et al., 2007; Y.W. CHOI, et al., 2007
  chr18:18,510,899-43,242,321    24,731,423      q11.1 - q12.3       Loss    70      83.33333333   \>0.05    Lockwood WW, et al., 2007; Y.W. CHOI, et al., 2007
  chr18:62,450,433-71,009,737    8,559,305       q22.1 - q22.3       Loss    11      83.33333333   \>0.05    Lockwood WW, et al., 2007; G Ng, et al., 2007
  chr19:1,271,138-4,752,741      3,481,604       p13.3               Gain    105     83.33333333   \>0.05    Y.W. CHOI, et al., 2007
  chr19:12,747,550-14,740,086    1,992,537       p13.13 - p13.12     Gain    56      83.33333333   \>0.05    Gopeshwar Narayan, et al., 2007
  chr19:16,170,761-19,780,245    3,609,485       p13.12 - p13.11     Gain    103     83.33333333   \>0.05    N/A
  chr19:45,216,651-51,316,691    6,100,041       q13.32 - q13.33     Gain    201     83.33333333   \>0.05    Lockwood WW, et al., 2007
  chr19:55,542,540-56,189,743    647,204         q13.42              Gain    31      83.33333333   \>0.05    N/A
  chr19:58,530,030-59,114,839    584,810         q13.43              Gain    23      83.33333333   \>0.05    N/A
  chr20:60,195,293-62,965,520    2,770,228       q13.33              Gain    63      83.33333333   \>0.05    Connie P. Matthews, et al., 2000; Y.W. CHOI, et al., 2007; G Ng, et al., 2007
  chr21:14,417,523-32,339,619    17,922,097      q11.2 - q22.11      Loss    61      83.33333333   \>0.05    N/A
  chrX:77,966,491-93,063,726     15,097,236      q21.1 - q21.32      Loss    25      83.33333333   \>0.05    Connie P. Matthews, et al., 2000
  chrX:120,138,580-127,769,411   7,630,832       q24 - q25           Loss    10      83.33333333   \>0.05    Connie P. Matthews, et al., 2000
  chrX:152,449,419-153,711,912   1,262,494       q28                 Gain    47      83.33333333   0         Gopeshwar Narayan, et al., 2007; Connie P. Matthews, et al., 2000

Eleven of these (5 amplification regions and 6 deletion regions) have not been previously described in cervical cancer (Table [1](#T1){ref-type="table"}). A total of 3514 genes were identified, and many tumor related genes, such as *ABL1*, *BCL3*, *CDH1*, *CDKN1C*, *EPHA3*, *ERBB4*, *FOSL1*, *JUNB*, *MLH1*, *MYB*, *p53*, *RB1*, *ROS1*, *SKI*, *TGFBR1* and *THRB*, were located in these 50 chromosomal CNV regions.

Chromosomal CNVs could contribute to their transcript expression in cervical cancer {#s2_2}
-----------------------------------------------------------------------------------

To evaluate if there is any association between chromosomal CNVs and gene expression changes in cervical cancer, we analyzed the gene expression profiles of the cervical cancer cell lines and normal cervical epithelium samples. 17.52% of transcripts (7,211 out of 41,152) exhibited a 2-fold over-expression and 9.02% of transcripts (3,712 out of 41,152) displayed a 2-fold down-regulation in 6 cervical cancer cell lines compared with 3 normal cervical epithelium tissues. Within the 21 common genomic amplification regions, 27.94% of the transcripts (772 out of 2,794) showed 2-fold over-expression. In the 13 significant amplification regions, the percentage was 29.56% (459 out of 1,553). In the 29 deletion regions, 10.46% (287 out of 2744) revealed 2-fold down-regulation. In the 2 significant deletion regions, the percentage was 11.67% (7 out of 60) (Figure [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). Statistical analysis showed that gene up-regulation or down-regulation was significantly correlated with genomic amplification (P \< 0.01, Spearsman correlation test) or deletion (P \< 0.01) events. Thus, chromosomal CNVs can contribute to their transcript expression in cervical cancer. Two tumor related genes, *ABL1* and *p53*, which were located in the genomic amplification regions, were found to be over-expressed by at least 2-fold in cervical cancer.

![Gene expression variation in different genomic regions\
**(A)** Percentage of up-regulated transcripts in whole genomic regions, common amplification regions and significant amplification regions. **(B)** Percentage of down-regulated transcripts in whole genomic regions, common deletion regions and significant deletion regions.](oncotarget-08-108912-g001){#F1}

Profiles differed between cervical cancer cell lines, primary cervical carcinoma and normal cervical epithelium tissues {#s2_3}
-----------------------------------------------------------------------------------------------------------------------

Expression profiles of transcripts across 6 different cervical cancer cell lines and 2 cervical carcinoma tissues and 3 normal, age-matched, cervical epithelium samples were analyzed using a hierarchical clustering algorithm (unsupervised K-means clustering). Cervical cancer cell lines, cervical carcinoma and normal cervical epithelium were divided two main groups (Figure [2A](#F2){ref-type="fig"}): cervical cancer cell lines for one group, and clinical cervical carcinoma and normal cervical epithelium for the other group. Interestingly, when gene tree clustering analysis was used to analyze genes with aberrant expression within the 50 common chromosome CNV regions and 15 significant chromosome CNV regions, similar results were obtained (Figure [2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"})

![Gene tree clustering analysis\
**(A)** Gene tree clustering analysis for the gene expression profiles of the cervical cancer cell lines, cervical carcinomas and normal cervical epithelium tissues; **(B)** gene tree clustering analysis for the aberrantly expressed genes in 50 common chromosomal CNV regions in cervical carcinoma; **(C)** gene tree clustering analysis for the aberrantly expressed genes in 15 significant chromosomal CNV regions in cervical carcinoma.](oncotarget-08-108912-g002){#F2}

Gene ontology analysis for aberrantly expressed genes {#s2_4}
-----------------------------------------------------

By using a volcano plot in GeneSpring, 9,446 transcripts (27.4%) were found to be changed over two fold in the "Cancer group" (including 6 cervical cancer cell lines and 2 clinical cervical carcinomas) compared with the "Normal group" (including 3 cervical epithelium tissues). Among these genes, 6,001 transcripts were up-regulated by over 2 fold, and 3,445 transcripts were down-regulated by over 2 fold.

Pathway analysis showed that cell cycle pathways, cell communication pathways and DNA polymerase pathways were significantly affected pathways in cervical cancer {#s2_5}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

To further investigate the biological significance of these aberrantly expressed genes, pathway analysis was performed. The analysis results showed that cycle cycle pathways (*P*=1.15e-8), cell communication pathways (*P*=1.15e-8) and DNA polymerase pathways (*P*=1.15e-8) were significantly were affected in the cervical cancer (Table [2](#T2){ref-type="table"}). Pathway analysis for the 446 differentially expressed transcripts in the 15 significant chromosomal CNV regions also showed that the cell cycle pathway involved the highest number of transcripts (including *ABL1*, *DUSP9*, *E2F4*, *TP53*, *PKMYT1* and *PPP1CA*) (Figure [3](#F3){ref-type="fig"}), and the *P* value is 0.00062 (Table [3](#T3){ref-type="table"}).

###### Pathway analysis for the differentially expressed genes in cervical cancer

  Pathway                                                                 Number of genes with each pathway   Genelist vs pathway random overlap p-value
  ----------------------------------------------------------------------- ----------------------------------- --------------------------------------------
  Cell cycle - Homo sapiens (human)                                       111                                 1.15E-08
  Proteasome - Homo sapiens (human)                                       27                                  2.66E-08
  One carbon pool by folate - Homo sapiens (human)                        22                                  5.11E-07
  Cell Communication - Homo sapiens (human)                               60                                  5.85E-07
  Pyrimidine metabolism - Homo sapiens (human)                            52                                  6.05E-06
  Purine metabolism - Homo sapiens (human)                                77                                  2.27E-05
  DNA polymerase - Homo sapiens (human)                                   19                                  5.80E-05
  Arginine and proline metabolism - Homo sapiens (human)                  35                                  0.000103
  Riboflavin metabolism - Homo sapiens (human)                            14                                  0.00036
  gamma-Hexachlorocyclohexane degradation - Homo sapiens (human)          17                                  0.000515
  Hematopoietic cell lineage - Homo sapiens (human)                       45                                  0.000654
  Valine, leucine and isoleucine biosynthesis - Homo sapiens (human)      10                                  0.000804
  Glycosphingolipid biosynthesis - ganglioseries - Homo sapiens (human)   13                                  0.000894
  Pathogenic Escherichia coli infection - EHEC - Homo sapiens (human)     33                                  0.000941
  Pathogenic Escherichia coli infection - EPEC - Homo sapiens (human)     33                                  0.000941
  Selenoamino acid metabolism - Homo sapiens (human)                      23                                  0.00105
  Valine, leucine and isoleucine degradation - Homo sapiens (human)       31                                  0.00139
  Urea cycle and metabolism of amino groups - Homo sapiens (human)        17                                  0.00172
  ECM-receptor interaction - Homo sapiens (human)                         46                                  0.00179
  Glycan structures - biosynthesis 2 - Homo sapiens (human)               36                                  0.00261
  2,4-Dichlorobenzoate degradation - Homo sapiens (human)                 6                                   0.00264
  Butanoate metabolism - Homo sapiens (human)                             24                                  0.00302
  Lysine degradation - Homo sapiens (human)                               30                                  0.00449
  Aminoacyl-tRNA biosynthesis - Homo sapiens (human)                      17                                  0.0047
  Cell adhesion molecules (CAMs) - Homo sapiens (human)                   63                                  0.0062
  Folate biosynthesis - Homo sapiens (human)                              22                                  0.00732
  Ascorbate and aldarate metabolism - Homo sapiens (human)                10                                  0.00742
  Histidine metabolism - Homo sapiens (human)                             22                                  0.00918
  Alkaloid biosynthesis II - Homo sapiens (human)                         14                                  0.0101
  Limonene and pinene degradation - Homo sapiens (human)                  18                                  0.0102
  Focal adhesion - Homo sapiens (human)                                   91                                  0.0108
  Methionine metabolism - Homo sapiens (human)                            11                                  0.0112
  Oxidative phosphorylation - Homo sapiens (human)                        49                                  0.012
  Citrate cycle (TCA cycle) - Homo sapiens (human)                        16                                  0.0153
  Glycosaminoglycan degradation - Homo sapiens (human)                    11                                  0.016
  Nitrobenzene degradation - Homo sapiens (human)                         10                                  0.0165
  Olfactory transduction - Homo sapiens (human)                           17                                  0.0179
  Glycolysis Gluconeogenesis - Homo sapiens (human)                       31                                  0.0197
  Ethylbenzene degradation - Homo sapiens (human)                         11                                  0.0221
  Ubiquitin mediated proteolysis - Homo sapiens (human)                   26                                  0.0236
  Glyoxylate and dicarboxylate metabolism - Homo sapiens (human)          9                                   0.0243
  Arachidonic acid metabolism - Homo sapiens (human)                      25                                  0.0306
  N-Glycan biosynthesis - Homo sapiens (human)                            21                                  0.033
  Chondroitin sulfate biosynthesis - Homo sapiens (human)                 7                                   0.037
  Linoleic acid metabolism - Homo sapiens (human)                         17                                  0.0415
  Pentose phosphate pathway - Homo sapiens (human)                        14                                  0.0465
  Apoptosis - Homo sapiens (human)                                        38                                  0.0467
  Protein export - Homo sapiens (human)                                   8                                   0.0498

![Cell cycle pathway analysis in cervical cancer\
**(A)** Differently expressed genes involved in the cell cycle pathway in cervical carcinoma; **(B)** differently expressed genes within the significant chromosomal CNV regions involved in the cell cycle pathway in cervical carcinoma. Each rectangle represents one gene. The rectangle covered by gray color indicates that this gene is differently expressed in cervical carcinoma compared with normal cervix.](oncotarget-08-108912-g003){#F3}

###### Pathway analysis for the differentially expressed genes within the 15 significant chromosome CNV regions in cervical cancer

  Pathway                                                                 Number of common genes with each pathway   Genelist vs pathway random overlap p-value
  ----------------------------------------------------------------------- ------------------------------------------ --------------------------------------------
  Cell cycle - Homo sapiens (human)                                       11                                         0.000622
  Purine metabolism - Homo sapiens (human)                                7                                          0.0126
  Axon guidance - Homo sapiens (human)                                    6                                          0.0365
  Insulin signaling pathway - Homo sapiens (human)                        6                                          0.0386
  Selenoamino acid metabolism - Homo sapiens (human)                      5                                          0.000365
  Tyrosine metabolism - Homo sapiens (human)                              5                                          0.00382
  Glycerophospholipid metabolism - Homo sapiens (human)                   5                                          0.00419
  Tryptophan metabolism - Homo sapiens (human)                            5                                          0.0137
  Nitrobenzene degradation - Homo sapiens (human)                         4                                          0.000101
  Aminophosphonate metabolism - Homo sapiens (human)                      4                                          0.000199
  Histidine metabolism - Homo sapiens (human)                             4                                          0.00452
  Androgen and estrogen metabolism - Homo sapiens (human)                 4                                          0.00747
  Glycan structures - biosynthesis 2 - Homo sapiens (human)               4                                          0.0281
  Sulfur metabolism - Homo sapiens (human)                                3                                          0.000724
  Ethylbenzene degradation - Homo sapiens (human)                         3                                          0.00309
  RNA polymerase - Homo sapiens (human)                                   3                                          0.00781
  1- and 2-Methylnaphthalene degradation - Homo sapiens (human)           3                                          0.0136
  Benzoate degradation via CoA ligation - Homo sapiens (human)            3                                          0.0153
  Limonene and pinene degradation - Homo sapiens (human)                  3                                          0.0153
  Pyruvate metabolism - Homo sapiens (human)                              3                                          0.0362
  Bisphenol A degradation - Homo sapiens (human)                          2                                          0.0233
  Glycosphingolipid biosynthesis - ganglioseries - Homo sapiens (human)   2                                          0.03
  Dentatorubropallidoluysian atrophy (DRPLA) - Homo sapiens (human)       2                                          0.0323
  Parkinson\'s disease - Homo sapiens (human)                             2                                          0.0323

DISCUSSION {#s3}
==========

In our genome-wide CNV analysis, we identified 50 frequently altered genomic regions (ranging from 0.5 Mb to 80 Mb), of which 11 have not been previously described in cervical cancer (Table [1](#T1){ref-type="table"}). These differences in our results may be due to the different platforms of assay, different settings of analysis or the different cervical cancer cells. In these 50 commonly altered genomic regions, 3514 genes are included. Some of these, especially oncogenic or tumor suppressor genes, may be associated with the development of cervical cancer.

The gene tree clustering result suggested that during the development of cervical carcinoma, gene expression significantly changes, and cervical carcinoma can be distinguished from normal cervical epithelium tissue by clustering analysis of the gene expression profile. Since the cervical cancer cell lines were separate from primary cervical carcinoma and normal cervical epithelium tissue, we assumed that extended culturing of cervical cancer cell lines may also significantly alter their gene expression profiles.

The integrated analysis of genome-wide chromosomal copy number changes and gene expression profiling indicated that the identified CNVs could contribute to the expression of some but not all genes (Figure [1](#F1){ref-type="fig"}). This finding is consistent with a report by Vazquez-Mena et al. which used a different array platform to detect the correlation between CNVs and gene expression variation in cervical cancer cell lines. Other factors, such as epigenetic changes or transcription factors, may also contribute to variation of gene expression in cervical cancer \[[@R4]\]. Pathway analysis indicated that significant changes of some pathways, especially those involving the cell cycle, may be involved in the pathogenesis of cervical cancer.

*ABL1 and p53*, the two cell cycle pathway tumor-related genes which were located in the significant genomic amplification regions, were found to be overexpressed at least 2-fold in cervical cancer. *ABL1,* which was located in the chr9:128,223,213-139,309,447 genomic amplification region, plays a role in apoptosis. *p53* is a well-known tumor suppressor gene, and an increase in *p53* levels plays a critical role in the induction of genes that results in cell cycle arrest \[[@R7]\], allowing repair of damaged DNA or activation of apoptotic pathways \[[@R8]\]. In cervical cancer with high risk of HPV-infection, the E6 protein from high-risk HPV can bind to tumor suppressor protein p53 for rapid degradation via a cellular ubiquitin ligase \[[@R9]\]. Other studies have indicated that p53 protein over-expression is not common or associated with survival in cervical carcinoma \[[@R10], [@R11]\]. However, from our array CGH and gene expression array data, *p53* was located in the chr17:7,175,150-8,229,647 genomic amplification region and was over-expressed at the mRNA level (the median of the expression of *p53* in cervical cancer cell lines was 1.316 \[from 0.82 to 3.38); the median of the expression of *p53* in normal cervical epithelium was 0.295 \[from 0.153 to 0.485\]). This suggests that gene dosage of *p53* contributes to RNA over-expression in some cervical cancers.

Our results demonstrated that over-expression of transforming growth factor-beta 1 (TGF-β1), a gene important in cell cycle pathways, may be due to a chromosomal CNV. TGF-β1 was amplified and was also over-expressed (\>2 fold) in the cancer group compared with the normal group. TGF-β1 is involved in many different critical processes, such as embryonic development, cellular maturation and differentiation, wound healing, immune regulation and inflammation. TGF-β1 is a potent inhibitor of cell proliferation at the beginning of carcinogenesis \[[@R12], [@R13]\]. When cells become resistant to TGF-β1, tumor growth may be enhanced and metastasis promoted via immune evasion and angiogenesis. An increased expression of TGF-β1 has been found in cervical cancer. Kirma et al. suggested that TGF-β1 may be a factor in inducing over-expression of an oncogene, c-fms. Blocking c-fms has been demonstrated to result in increased apoptosis and decreased motility in cervical cancer \[[@R14]\].

Matrix metalloproteinases (MMPs) play an important role in the enhancement of tumor-induced angiogenesis. Our aCGH data showed that 9 MMP genes (MMP1, 3, 7, 8, 10, 12, 13, 20 and 27) located within 11q22 are amplified in Caski and SiHa cell lines, consistent with Lockwood's findings. Further analysis revealed that MMP14, 23B and 25 were located in significant genomic amplification regions and MMP1, 15, 17 and TIMP1 in all our 6 cervical cancer cell lines. This is consistent with previous work reporting over-expression of MMP12 and MMP15 \[[@R15]-[@R19]\].

In summary, we have identified several chromosomal CNV regions and demonstrated that chromosomal CNVs are a common phenomenon which can affect the level of RNA expression in cervical cancer. Pathway analysis for the aberrantly expressed genes suggested that significant changes of some pathways, especially those involving the cell cycle, may contribute to the pathogenesis of cervical cancer. This study provided some clinical significance for us to have a better understanding of cervical cancer pathogenesis.

MATERIALS AND METHODS {#s4}
=====================

Cervical cancer cell lines and specimens {#s4_1}
----------------------------------------

Six human cervical cancer cell lines (HeLa, SiHa, C33A, ME180, CC2 and CC3) were used for aCGH and gene expression array. Five clinical specimens, including three normal cervical tissues and two cervical carcinoma specimens (FIGO stage: II~A~), were collected from patients (aged between 36-42 years old) at the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital in Hong Kong from January 2014 to December 2014. Informed consent was obtained from all participating subjects, and Institutional Review Board approval was obtained.

Tissue micro-dissection {#s4_2}
-----------------------

Micro-dissection was used as described in our previous study \[[@R5]\]. Briefly, the tissue specimens were frozen in OCT cryomoulds (SAKURA, Japan), sectioned (8 μm) by a cryostat at -20°C (Leica Corp., CRYOCUT 1800), and then mounted onto glass slides (SAIL BRAND, Cat No 7105) at room temperature. Sections were stained by 0.1% methyl green (Sigma) and micro-dissected using a sterile surgical blade (AESCULAP) and collected immediately for further experiments.

Microarray comparative genomic hybridization analysis {#s4_3}
-----------------------------------------------------

Microarray comparative genomic hybridization using Human Genome CGH Microarray Kit (4x44K) (Agilent Technologies, Santa Clara, CA, USA) was used for identifying chromosomal CNV of 6 cervical cancer cell lines and 3 normal cervical samples as per the manufacturer's protocol. Briefly, genomic DNA of cervical cancer cell lines was extracted using a DNeasy Blood & Tissue Kit (QIAGEN, Cat No. 69506). 1 μg genomic DNA of test sample and 1 μg human sex-matched control DNA as a reference sample (Promega G1521A; Lot no. 20929604) were digested using Alu I and Rsa I. This was followed by fluorescent labeling, clean-up of labeled genomic DNA, microarray hybridization and scanning. The data were extracted using the Agilent Feature Extraction (FE) v11.0 program. After calculating the background signal, non-uniform signal and the average raw signal on each probe, the resulting data files were generated and transferred to the bioinformatics software, Nexus Copy Number version 6.1 (BioDiscovery, Inc., El Segundo, CA, USA) for analysis \[[@R6]\].

Gene expression analysis {#s4_4}
------------------------

The Whole Human Genome Microarray Kit, 4x44K (G4112F) was used to probe gene expression in 6 cervical cancer cell lines, 2 cervical carcinomas and 3 normal cervical epithelium tissue samples. The resulting data files were generated and transferred to GeneSpring GX version 11.5 (Agilent Technologies, Santa Clara, CA, USA) for further analysis.

Reverse transcription PCR (RT-RCR) {#s4_5}
----------------------------------

RT-RCR was peformed for the identified gain and loss genes both on expression level and on genome level, normalized by GAPDH and B-globin (Forward: 5'-GAAGAGCCAAGGACAGGTAC-3', Reverse: 5'-CAACTTCATCCACGTTCACC-3'), B2M (Forward:5'-TGCTGTCTCCATGTTTGATGTATCT-3';Reverse:5'-TCTCTGCTCCCCACCTCTAAGT-3'), respectively.

Statistical analysis {#s4_6}
--------------------

For the Microarray Comparative Genomic Hybridization Analysis, 0.37 was used as the cut off value for amplification or 0.5 for deletion of a single probe. Putative chromosome copy number changes were defined by intervals of three or more adjacent probes with log~2~ ratios suggestive of a deletion or duplication when compared with the log~2~ ratios of adjacent probes. The p value for significant difference was set to less than 0.05 to reduce the false discovery rate (FDR). For **Gene Expression Analysis,** the cut-off value defining an aberrant change of gene expression was set at 2 fold for data analysis. Pathway analysis for the gene expression data was performed by GeneSpring GX version 11.5, and the pathway was downloaded from the KEGG database (<ftp://ftp.genome.jp/pub/kegg/>).
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CNV
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HPV
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